Rob Pieters

Active 1988–2025

215
Papers
31,334
Citations
105
h-index
209
i10-index

Citations

Citations per year for Rob Pieters1989: 2 citations1990: 10 citations1991: 11 citations1992: 7 citations1993: 4 citations1994: 15 citations1995: 24 citations1996: 22 citations1997: 25 citations1998: 39 citations1999: 22 citations2000: 50 citations2001: 38 citations2002: 76 citations2003: 154 citations2004: 135 citations2005: 183 citations2006: 135 citations2007: 162 citations2008: 247 citations2009: 279 citations2010: 317 citations2011: 315 citations2012: 295 citations2013: 292 citations2014: 288 citations2015: 346 citations2016: 325 citations2017: 298 citations2018: 219 citations2019: 884 citations2020: 962 citations2021: 979 citations2022: 639 citations2023: 453 citations2024: 818 citations2025: 278 citations2026: 7 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,577 citing papers, 23.9% of this breakdownGermany: 742 citing papers, 6.9% of this breakdownChina: 740 citing papers, 6.8% of this breakdownUnited Kingdom: 691 citing papers, 6.4% of this breakdownNetherlands: 677 citing papers, 6.3% of this breakdownItaly: 517 citing papers, 4.8% of this breakdownFrance: 438 citing papers, 4.1% of this breakdownCanada: 325 citing papers, 3% of this breakdownAustralia: 316 citing papers, 2.9% of this breakdownSpain: 275 citing papers, 2.5% of this breakdownJapan: 256 citing papers, 2.4% of this breakdownBelgium: 218 citing papers, 2% of this breakdown
0%23.9%Other 28%

Fields

  • Medicine60.5%
  • Biochemistry, Genetics and Molecular Biology31.1%
  • Computer Science2.6%
  • Immunology and Microbiology1.9%
  • Agricultural and Biological Sciences0.5%
  • Chemistry0.5%
  • Other2.9%

Topics

  • Acute Lymphoblastic Leukemia research12%
  • Acute Myeloid Leukemia Research7.6%
  • Childhood Cancer Survivors' Quality of Life5.5%
  • Chronic Myeloid Leukemia Treatments3.6%
  • Epigenetics and DNA Methylation2.6%
  • Gene expression and cancer classification2.6%
  • Other66.1%

Coauthors

All papers

Open in search
  1. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 1,003

  2. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 204

  3. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

    Authors: , , , , , , , , , - Nature Genetics 2001 cited by 1,719

  4. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

    Authors: , , , , , , , , , , , , , , - The Lancet Oncology 2009 cited by 925

  5. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 299

  6. T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies

    Authors: , , , , - Blood Cancer Discovery 2020 cited by 144

  7. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood Advances 2022 cited by 85

  8. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern

    Authors: , , , , , , , , , , , , , , , , , - Blood 2011 cited by 335

  9. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 370

  10. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Webb, Zuzana Zemanová, C. Michel Zwaan, Marry M. van den Heuvel‐Eibrink - Blood 2009 cited by 447

  11. Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 41

  12. L‐asparaginase treatment in acute lymphoblastic leukemia

    Authors: , , , , , , , , - Cancer 2010 cited by 566

  13. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2007 cited by 653

  14. Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2011 cited by 382

  15. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL

    Authors: , , - Journal of Clinical Oncology 2023 cited by 60

  16. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Josef Vormoor, Eelco W. Hoving, Max M. van Noesel, Rob Pieters, Marcel Kool, Miriam Stumpf, Mirjam Blattner-Johnson, Gnana Prakash Balasubramanian, Cornelis M. van Tilburg, Barbara C. Jones, David Jones, Olaf Witt, Stefan M. Pfister, Marjolijn C.J. Jongmans, Roland P. Kuiper, Ronald R. de Krijger, Marc H W Wijnen, Monique L. den Boer, C. Michel Zwaan, Patrick Kemmeren, Jan Köster, Bastiaan B.J. Tops, Bianca F. Goemans, Jan J. Molenaar - European Journal of Cancer 2022 cited by 60

  17. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

    Authors: , , , , , , , , , , , , , - The Journal of Experimental Medicine 2007 cited by 662

  18. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charles G. Mullighan, Atsushi Manabe, Gabriele Escherich, Jerzy Kowalczyk, James A. Whitlock, C. Michel Zwaan - Blood 2013 cited by 247

  19. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2012 cited by 335

  20. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

    Authors: , , , , , , , , , , - Haematologica 2016 cited by 239

  21. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linda Holmfeldt, Charles G. Mullighan, Monique L. den Boer, Rob Pieters, Sima Jeha, Thomas L. Dunwell, Farida Latif, Deepa Bhojwani, William L. Carroll, Ching‐Hon Pui, R Myers, R. Kiplin Guy, Thirumala‐Devi Kanneganti, Mary V. Relling, William E. Evans - Nature Genetics 2015 cited by 160

  22. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2020 cited by 66

  23. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment

    Authors: , , , - Blood 2015 cited by 171

  24. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 74